ClinicalTrials.gg
CompletedNCT06841731Updated Oct 22, 2026

A Trial of HRS-8427 in the Treatment of Adults With Bacterial Pneumonia

A Phase 2 interventional study of HRS-8427 and Meropenem in Hospital-acquired Bacterial Pneumonia (HABP) and Ventilator-associated Bacterial Pneumonia (VABP), sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

Updated Oct 22, 2026Now CompletedNow Active, not recruiting+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Pneumonia, Bacterial with a site in China — 6 open to participants now, 6 under way, 2 of them phase 3. Pneumonia, Bacterial · China.

Started
2025
the only one that year
Phase 2
3 of 10
2 open now
Registered
6th of 10
by date
Lead sponsor
1 of 10
Jiangsu HengRui Medicine Co., Ltd.

Among the 10 studies in Pneumonia, Bacterial with a site in China, this one is the only one that started in 2025, is one of 3 in phase 2, and was the 6th registered.

Pneumonia, Bacterial

153 studies on the registry are indexed under Pneumonia, Bacterial; 27 are open to participants now.

Browse Pneumonia, Bacterial studies →

Open to participants now

6 of the 10 studies in Pneumonia, Bacterial with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 18 Pneumonia, Bacterial studies recruiting now, 12 (67%) set no upper age limit and 2 (11%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Pneumonia, Bacterial with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of HRS -8427 in patients with HABP/VABP.

03

Conditions studied

  • Hospital-acquired Bacterial Pneumonia (HABP)
  • Ventilator-associated Bacterial Pneumonia (VABP)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be able and willing to provide a written before the study, fully understand the study and be able to complete the study according to the protocol.
  2. Male and female, ≥18 years.
  3. Judged by the investigator, clinical diagnosis with HABP/VABP, expectation that the patients will require hospitalization and initial treatment with intravenous antibiotics.
  4. All subjects must have a chest radiograph during screening or within 48h before randomization, showing the presence of new or progressive infiltrate(s) suggestive of bacterial pneumonia.
  5. Women of must have a negative serum pregnancy test before the first dose and must be non-lactating. Fertile female subjects or male subjects whose partner is a fertile female agree to use highly effective form of , with no plan of birth and sperm/ovum donation from the time of signing the informed consent form (ICF) till 14 days after the end of treatment.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have known or suspected community-acquired bacterial pneumonia (CABP), atypical pneumonia, or chemical pneumonia.
  2. Subjects who have known or suspected pneumonia caused by mycoplasma, chlamydia, legionella, viruses, fungi or parasites.
  3. HABP or VABP caused by obstruction.
  4. Subjects who have received potentially effective antibiotic therapy for a continuous duration of more than 24 hours during the previous 72 hours prior to randomization.
  5. Impairment of renal function with estimated \< 15 mL/min, or receiving peritoneal dialysis/hemodialysis.
  6. Subjects with significant laboratory abnormalities.
  7. Other pulmonary diseases that may confound the assessment of efficacy or safety.
  8. Known history of immune deficiency disease or receive immunocompromising treatment.
  9. Severe cardiovascular and cerebrovascular diseases with clinical significance and unstable or uncontrolled condition.
  10. Known or suspected central nervous system infections.
  11. Patients received cancer treatment within 4 weeks before randomization or planned treatment during the study period.
  12. Drug abuse within 1 year prior to randomization.
  13. Judged by the Investigator, other reasons unsuitable for this study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    HRS-8427

    Drug: HRS-8427

  • Active comparator
    Meropenem

    Drug: Meropenem

Interventions

06

What researchers measure

Primary outcomes

  1. The all-cause mortality rate at Day 14.

    Time frame: From the first dose of the study drug to Day 14.

Secondary outcomes

  1. The all-cause mortality rate at Day 28.

    Time frame: From the first dose of the study drug to Day 28.

  2. The total ventilation time.

    Time frame: Day 14 to Day 21.

  3. The total ventilation time.

    Time frame: Day 21 to Day 28.

  4. The percentage of participants with microbiologic eradication at the early assessment (EA) period.

    Time frame: Day 4 after the start of the treatment.

  5. The percentage of participants with microbiologic eradication at the end of treatment (EOT) period.

    Time frame: Day 7 to 14.

  6. The percentage of participants with microbiologic eradication at the test of cure (TOC) period.

    Time frame: Day 14 to 21.

  7. The percentage of participants with microbiologic eradication at the follow-up (FU) period.

    Time frame: Day 21 to 28.

07

Study locations

1 site
  • China-Japan Friendship Hospital
    Beijing, Beijing Municipality 100029, China
08

References and documents

Publications

  • Yin T, Qu B, Zhang Q, Xu S, Wu Y, Jiang H, Huang Y, Hu W. Pharmacokinetics, safety, and tolerability of HRS-8427, a novel anti-carbapenem-resistant cephalosporin, in healthy subjects. Antimicrob Agents Chemother. 2026 Apr;70(4):e0069425. doi: 10.1128/aac.00694-25. Epub 2026 Mar 3. PubMed 41773934 ↗
  • Wu Y, Han Q, Yang H, Xue J, Wang L, Mao X, Yin T, Jiang H, Xu S, Huang Y, Wang T, He Y, Luo Y, Chen W, Zhang J. Effects of renal impairment and hemodialysis on the pharmacokinetics and safety of HRS-8427, a siderophore cephalosporin for Gram-negative bacterial infections. Antimicrob Agents Chemother. 2026 Feb 4;70(2):e0109525. doi: 10.1128/aac.01095-25. Epub 2026 Jan 13. PubMed 41528248 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Apr 2025 to primary completion in Sep 2026, 17 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Feb 2026 → Sep 2026 and completion Feb 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2025
First posted
Feb 24, 2025
StartActual
Apr 10, 2025
Primary completionActual
Sep 22, 2026was Feb 2026
CompletionActual
Oct 9, 2026was Feb 2026
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting→Completed
changed Sep 30, 2026 · changed Oct 22, 2026
Sites
1 site added, 1 site removed
Show site
  • China-Japan Friendship Hospital · Beijing, China
Show 1 removed
  • China-Japan Friendship Hospital · Beijing, China
Sep 30, 2026
Start date
Apr 3, 2025→Apr 10, 2025
Sep 30, 2026
Primary completion
Feb 2026→Sep 22, 2026 (actual)
Sep 30, 2026
Study completion
Feb 2026→Oct 2026
Sep 30, 2026
Enrollment
100 (estimated)→120 (actual)
Sep 30, 2026
Publications
2 publications citing this study linked from PubMed, e.g. PubMed 41773934 ↗
Sep 30, 2026
Show all 2 updates
  1. Oct 22, 2026
    Active, not recruiting→Completed
    + 1 other change: date precision
  2. Sep 30, 2026
    Recruiting→Active, not recruiting
    Publications 2 publications citing this study linked from PubMed, e.g. PubMed 41773934 ↗
    1 site added, 1 site removed
    Show site
    • China-Japan Friendship Hospital · Beijing, China
    Show 1 removed
    • China-Japan Friendship Hospital · Beijing, China
    Start date Apr 3, 2025→Apr 10, 2025
    Primary completion Feb 2026→Sep 22, 2026 (now actual)
    Study completion Feb 2026→Oct 2026
    Enrollment 100 (estimated)→120 (actual)
    + 3 other changes: index terms, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06841731
Responsible party
Sponsor
First posted
Feb 24, 2025
Start date
Apr 10, 2025
Primary completion
Sep 22, 2026
Completion
Oct 9, 2026
Last update
Oct 22, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-8427

Start the discussion